Short Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Expands By 26.2%

CytomX Therapeutics, Inc. (NASDAQ:CTMX) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 5,540,000 shares, a growth of 26.2% from the November 30th total of 4,390,000 shares. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is currently 4.8 days.

Institutional Trading of CytomX Therapeutics

Several large investors have recently made changes to their positions in CTMX. US Bancorp DE bought a new stake in CytomX Therapeutics during the third quarter worth $40,000. XTX Topco Ltd lifted its position in shares of CytomX Therapeutics by 382.6% during the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after buying an additional 48,033 shares during the last quarter. Forefront Analytics LLC boosted its stake in CytomX Therapeutics by 206.7% in the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 43,176 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in CytomX Therapeutics by 96.6% in the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 40,309 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in CytomX Therapeutics during the third quarter worth about $104,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Stock Performance

Shares of CytomX Therapeutics stock opened at $1.02 on Tuesday. The firm has a 50-day moving average of $1.05 and a 200-day moving average of $1.18. CytomX Therapeutics has a 52-week low of $0.83 and a 52-week high of $5.85. The stock has a market cap of $79.82 million, a PE ratio of 6.00 and a beta of 1.07.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.23. The company had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period in the prior year, the firm posted $0.04 EPS. Equities research analysts predict that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research note on Monday, November 11th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.